Yukon Wealth Management Inc. Acquires Shares of 4,470 Johnson & Johnson (NYSE:JNJ)

Yukon Wealth Management Inc. bought a new position in Johnson & Johnson (NYSE:JNJ) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 4,470 shares of the company’s stock, valued at approximately $741,000.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Brighton Jones LLC grew its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the period. Hudson Value Partners LLC boosted its stake in Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock valued at $5,648,000 after acquiring an additional 1,022 shares during the last quarter. Bedel Financial Consulting Inc. grew its position in shares of Johnson & Johnson by 7.0% during the 4th quarter. Bedel Financial Consulting Inc. now owns 14,878 shares of the company’s stock valued at $2,301,000 after acquiring an additional 973 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Johnson & Johnson by 3.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 18,187,082 shares of the company’s stock worth $2,630,216,000 after purchasing an additional 547,714 shares during the last quarter. Finally, Bahl & Gaynor Inc. raised its holdings in shares of Johnson & Johnson by 303.0% in the 4th quarter. Bahl & Gaynor Inc. now owns 1,328,414 shares of the company’s stock worth $192,115,000 after purchasing an additional 998,761 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. The Goldman Sachs Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Wall Street Zen upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 21st. Royal Bank Of Canada reiterated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Trading Up 0.2%

Johnson & Johnson stock opened at $155.90 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The stock has a market cap of $375.11 billion, a P/E ratio of 17.34, a PEG ratio of 2.35 and a beta of 0.41. The firm’s fifty day moving average price is $153.65 and its 200-day moving average price is $153.96.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.34%. Johnson & Johnson’s payout ratio is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.